Anouk M. E. Jansen

Anouk M. E. Jansen

Auto-generated profile, based on publicly available information

Anouk M. E. Jansen

Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center , Nijmegen

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2022 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
AJAnouk M.E. Jansen
Anouk M.E. Jansen
EMEline W. Muilwijk
Eline W. Muilwijk
WVWalter J.F.M. van der Velden
Walter J.F.M. van der Velden
JMJohan A. Maertens
Johan A. Maertens
RARobina Aerts
Robina Aerts
RBRoger J.M. Brüggemann
Roger J.M. Brüggemann
This study aimed to describe the absolute oral bioavailability of the solid oral formulation of posaconazole and the impact of severe intestinal mucositis in haematology patients. This study also aimed to describe posaconazole protein binding in haematology patients. A pharmacokinetic study was performed of patients receiving induction chemotherapy or a haematopoietic cell transplantation who were randomized to receive 7 days of intravenous posaconazole therapy followed by 9 days of oral therapy, or vice versa. Patients received a posaconazole licensed dose until day 12, after which a reduced once-daily dose of 200 mg was given. At days 7, 12, and 16, blood samples were obtained for pharmacokinetic curves, and trough samples were collected on all other days. Total and unbound posaconazole pharmacokinetics were analyzed by population pharmacokinetic modelling. The presence of severe intestinal mucositis was assessed by plasma citrulline levels and analyzed as a binary covariate using 10 μmol/L as the cut-off. Monte Carlo simulations were performed to simulate posaconazole exposure at a steady state. Twenty-three patients were included for analysis, with 581 total posaconazole concentrations and 91 paired unbound concentrations. Absolute bioavailability in the final model was estimated at 51.4% (percentage relative standard error (%RSE): 56.5) and 67.6% (%RSE: 75.0) in patients with and without severe intestinal mucositis, respectively. Posaconazole unbound fraction was estimated at 2.7% (%RSE: 3.9). Posaconazole bioavailability is reduced in haematological patients with severe intestinal mucositis, requiring an increase in oral posaconazole dose to 400 mg twice daily on day 1, followed by 400 mg once daily or a switch to intravenous therapy.

11 October 2023 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
AJAnouk M. E. Jansen
Anouk M. E. Jansen
BMBeatrijs Mertens
Beatrijs Mertens
ISIsabel Spriet
Isabel Spriet
PVPaul Verweij
Paul Verweij
JSJeroen Schouten
Jeroen Schouten
RBRoger J. M. Brüggemann
Roger J. M. Brüggemann
Background and Objectives Isavuconazole is a broad-spectrum antifungal agent for the management of invasive fungal disease. Optimised drug exposure is critical for patient outcomes, specifically in the critically ill population. Solid information on isavuconazole pharmacokinetics including protein binding in patients in the intensive care unit is scarce. We aimed to describe the total and unbound isavuconazole pharmacokinetics and subsequently propose a dosage optimisation strategy. Methods A prospective multi-centre study in adult intensive care unit patients receiving isavuconazole was performed. Blood samples were collected on eight timepoints over one dosing interval between days 3–7 of treatment and optionally on one timepoint after discontinuation. Total and unbound isavuconazole pharmacokinetics were analysed by means of population pharmacokinetic modelling using NONMEM. The final model was used to perform simulations to assess exposure described by the area under the concentration–time curve and propose an adaptive dosing approach. Results Population pharmacokinetics of total and unbound isavuconazole were best described by an allometrically scaled two-compartment model with a saturable protein-binding model and interindividual variability on clearance and the maximum binding capacity. The median (range) isavuconazole unbound fraction was 1.65% (0.83–3.25%). After standard dosing, only 35.8% of simulated patients reached a total isavuconazole area under the concentration–time curve > 60 mg·h/L at day 14. The proposed adaptive dosing strategy resulted in an increase to 62.3% of patients at adequate steady-state exposure. Conclusions In critically ill patients, total isavuconazole exposure is reduced and protein binding is highly variable. We proposed an adaptive dosing approach to enhance early treatment optimisation in this high-risk population. Clinical Trial Registration ClinicalTrials.gov identifier: NCT04777058.

27 April 2024 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MEMehmet Ergün
Mehmet Ergün
AJAnouk M E Jansen
Anouk M E Jansen
LHLuuk B Hilbrands
Luuk B Hilbrands
EKElizabeth De Kort
Elizabeth De Kort
HKHenricus Kunst
Henricus Kunst
RBRoger J M Brüggemann
Roger J M Brüggemann
Isavuconazole is a relatively new antifungal agent indicated for the management of various invasive fungal diseases (IFDs), including invasive aspergillosis. Information on real-world experience with isavuconazole is scarce. This retrospective observational study aimed to describe the usage of isavuconazole in clinical practice with an in-depth evaluation of individual isavuconazole exposure. Patients treated with isavuconazole were evaluated based on retrospective data, including therapeutic drug monitoring (TDM) data and efficacy and safety data. Additionally, we calculated the individual isavuconazole exposure described by the average AUC24 over the first 7 days of treatment by means of non-linear mixed-effects modelling and compared this with the currently desired lower target AUC of 60 mg·h/L. Ninety-nine patients treated with isavuconazole were evaluated. In our real-life cohort, isavuconazole was often deployed off-label in patients with non-classical host factors and infections with non-Aspergillus and non-Mucorales species. Isavuconazole was most often chosen for its safety profile, even after prior triazole treatment with manifestations of toxicity. TDM and subsequent dosage adjustments were frequently performed. The individual average AUC24 over 7 days was above 60 mg·h/L in 29 out of 77 (37.7%) patients. This overview provides practical insights that can aid clinicians in the management of their patients with IFD. Our study shows that isavuconazole was used in a diverse patient population and was well tolerated overall. Individual isavuconazole exposure reflected by the average AUC24 over the first 7 days of treatment was generally low and variable. Dosage adjustments following TDM were frequently performed. Our experience shows that isavuconazole is a feasible alternative after prior azole treatment.

26 March 2024 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
AJAnouk M. E. Jansen
Anouk M. E. Jansen
KSKim Snijdelaar
Kim Snijdelaar
RKRon J. Keizer
Ron J. Keizer
ISIsabel Spriet
Isabel Spriet
EDErwin Dreesen
Erwin Dreesen
RHRob ter Heine
Rob ter Heine
Background and Objective Posaconazole is a pharmacotherapeutic pillar for prophylaxis and treatment of invasive fungal diseases. Dose individualization is of utmost importance as achieving adequate antifungal exposure is associated with improved outcome. This study aimed to select and evaluate a model-informed precision dosing strategy for posaconazole. Methods Available population pharmacokinetic models for posaconazole administered as a solid oral tablet were extracted from the literature and evaluated using data from a previously published prospective study combined with data collected during routine clinical practice. External evaluation and selection of the most accurate and precise model was based on graphical goodness-of-fit and predictive performance. Measures for bias and imprecision included mean percentage error (MPE) and normalized relative root mean squared error (NRMSE), respectively. Subsequently, the best-performing model was evaluated for its a posteriori fit-for-purpose and its suitability in a limited sampling strategy. Results Seven posaconazole models were evaluated using 764 posaconazole plasma concentrations from 143 patients. Multiple models showed adequate predictive performance illustrated by acceptable goodness-of-fit and MPE and NRMSE below ± 10% and ± 25%, respectively. In the fit-for-purpose analysis, the selected model showed adequate a posteriori predictive performance. Bias and imprecision were lowest in the presence of two prior measurements. Additionally, this model showed to be useful in a limited sampling strategy as it adequately predicted total posaconazole exposure from one (non-)trough concentration. Conclusion We validated an MIPD strategy for posaconazole for its fit-for-purpose. Thereby, this study is an important first step towards MIPD-supported posaconazole dosage optimization with the goal to improve antifungal treatment in clinical practice.

5 March 2024 in Medical Mycology
Verified
Journal Article
Open access
PDF file
AJAnouk M E Jansen
Anouk M E Jansen
MEMargot N Eggermont
Margot N Eggermont
EWErik Wilms
Erik Wilms
SASami Aziz
Sami Aziz
MRMonique Reijers
Monique Reijers
RMRenske van der Meer
Renske van der Meer
Limited data on the clinical management of drug–drug interactions between triazoles and Cystic Fibrosis transmembrane conductance regulator (CFTR) modulators are available. We retrospectively evaluated azole target attainment and dose adaptations in patients from two Dutch CF centres concomitantly receiving triazoles and CFTR modulators. In total, 21 patients with 59 triazole trough concentrations were evaluated. Subtherapeutic concentrations were frequently observed, especially for itraconazole and voriconazole. Of the investigated antifungal agents, posaconazole appears the most preferable option. Our results emphasize the importance of adequate management of this interaction and underpin the added value of therapeutic drug monitoring of triazoles in this population.

1 March 2021 in Clinical Lung Cancer
Verified
Journal Article
Open access
AJA.M.E. Jansen
A.M.E. Jansen
JSJ.D. Sriram
J.D. Sriram
DPD. Pluim
D. Pluim
RMR.J.H. Maas
R.J.H. Maas
HGH. van Groningen
H. van Groningen
RHR. ter Heine
R. ter Heine